New cancer-targeting therapy using platelet vector containing viral particles with anti-tumor activities
Project/Area Number |
25290056
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Tumor therapeutics
|
Research Institution | Osaka University |
Principal Investigator |
Kaneda Yasufumi 大阪大学, 医学(系)研究科(研究院), 教授 (10177537)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2015: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
|
Keywords | 腫瘍標的ベクター / HVJ envelope / 血小板 / 抗腫瘍免疫 / 癌 / 癌間質 / がん / 標的化 |
Outline of Final Research Achievements |
Inactivated Sendai virus (hemagglutinating virus of Japan; HVJ) envelope (HVJ-E) with anti-tumor activities were incorporated into mouse platelets.The hemagglutination activity which disturbs systemic administration of HVJ-E was dramatically attenuated by incorporation into platelets. Then, platelets incorporating HVJ-E (PH complex) were injected into the tail veins of B16F10 melanoma-bearing mice. The PH complex dominantly accumulated in tumor tissues and significantly suppressed melanoma growth in mice. Lung metastasis was also suppressed by susyemic administration of PH complex. Chemokine, IP-10, was also incorporated into platelet vector. The IP-10/platelet also suppressed melanoma growth in mic by systemic administration. Thus, the platelet vector incorporating anti-tumor reagents will provide a new approach for cancer-targeting therapy using oncolytic viruses.
|
Report
(4 results)
Research Products
(14 results)